Search Results for: ESR1

371 interactions involving ESR1 - estrogen receptor 1 found:

Sort by: Symbol Number of Pathways Number of Drugs Number of Diseases
Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
PTEN phosphatase and tensin homolog
  • Synthesis of PIPs at the plasma membrane
  • Synthesis of IP3 and IP4 in the cytosol
  • Negative regulation of the PI3K/AKT network
  • Downstream TCR signaling
  • TP53 Regulates Metabolic Genes
  • PTEN Loss of Function in Cancer
  • Ub-specific processing proteases
  • Ovarian tumor domain proteases
  • Regulation of PTEN mRNA translation
  • Regulation of PTEN localization
  • Regulation of PTEN stability and activity
  • Transcriptional Regulation by MECP2
  • Phosphatidylethanolamine
  • Vulvar cancer
  • Prostate cancer
  • Endometrial Cancer
  • Glioma
  • Small cell lung cancer
  • Breast cancer
  • Hepatocellular carcinoma
  • Malignant melanoma
PTGES3 prostaglandin E synthase 3
  • Synthesis of Prostaglandins (PG) and Thromboxanes (TX)
  • HSP90 chaperone cycle for steroid hormone receptors (SHR)
  • HSF1 activation
  • Attenuation phase
  • Aryl hydrocarbon receptor signalling
  • ESR-mediated signaling
  • Estrogen-dependent gene expression
  • Potential therapeutics for SARS
  • Acetaminophen
  • Grn163l
  • Copper
PTMA prothymosin alpha
PTPN1 protein tyrosine phosphatase non-receptor type 1
  • Integrin signaling
  • Negative regulation of MET activity
  • Regulation of IFNG signaling
  • PTK6 Down-Regulation
  • MECP2 regulates neuronal receptors and channels
  • Regulation of IFNA signaling
  • Growth hormone receptor signaling
  • Growth hormone receptor signaling
  • 3-(Oxalyl-Amino)-Naphthalene-2-Carboxylic Acid
  • 2-{[4-(2-Acetylamino-2-pentylcarbamoyl-ethyl)-naphthalen-1-YL]-oxalyl-amino}-benzoic acid
  • 5-(2-Fluoro-5-{(1E)-3-[3-hydroxy-2-(methoxycarbonyl)phenoxy]-1-propen-1-yl}phenyl)-1,2-oxazole-3-carboxylic acid
  • 2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Thiopyran-3-Carboxylic Acid
  • 3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid (4-Sulfamoyl-Phenyl)-Amide
  • [[4-(Aminomethyl)Phenyl]Amino]Oxo-Acetic Acid,
  • {4-[(2S)-2-({[(1S)-1-Carboxy-2-phenylethyl]carbamoyl}amino)-3-oxo-3-(pentylamino)propyl]phenoxy}malonic acid
  • Compound 19
  • 3-(4-{2-[2-(2-bromo-acetylamino)-ethyldisulfanyl]-ethylcarbamoyl}-cyclohexylcarbamoyl)-pyrazine-2-carboxylic acid
  • 2-(Oxalyl-Amino)-Benzoic Acid
  • {[2-(1h-1,2,3-Benzotriazol-1-Yl)-2-(3,4-Difluorophenyl)Propane-1,3-Diyl]Bis[4,1-Phenylene(Difluoromethylene)]}Bis(Phosphonic Acid)
  • Novo Nordisk a/S Compound
  • N-(Bromoacetyl)-beta-alanyl-N-(2-{4-[(carboxycarbonyl)amino]phenyl}ethyl)-L-serinamide
  • 7-(1,1-Dioxo-1h-Benzo[D]Isothiazol-3-Yloxymethyl)-2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Pyran-3-Carboxylic Acid
  • PNU177836
  • 2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Pyran-3-Carboxylic Acid
  • {[7-(Difluoro-Phosphono-Methyl)-Naphthalen-2-Yl]-Difluoro-Methyl}-Phosphonic Acid
  • 3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid [4-(Thiazol-2-Ylsulfamoyl)-Phenyl]-Amide
  • (4S)-5-[[(2S)-1-[[(2S)-1-Amino-3-[4-[difluoro(phosphono)methyl]phenyl]-1-oxopropan-2-yl]amino]-3-[4-[difluoro(phosphono)methyl]phenyl]-1-oxopropan-2-yl]amino]-4-benzamido-5-oxopentanoic acid
  • 4-[[(2S)-1-[[6-[(1-Amino-1-oxo-3-sulfanylpropan-2-yl)amino]-6-oxohexyl]amino]-3-[4-[difluoro(phosphono)methyl]phenyl]-1-oxopropan-2-yl]amino]-3-[[2-[4-[difluoro(phosphono)methyl]phenyl]acetyl]amino]-4-oxobutanoic acid
  • L-cysteic acid
  • 2-(Oxalyl-Amino)-4,5,6,7-Tetrahydro-Thieno[2,3-C]Pyridine-3-Carboxylic Acid
  • 4-Carbamoyl-4-{[6-(Difluoro-Phosphono-Methyl)-Naphthalene-2-Carbonyl]-Amino}-Butyric Acid
  • Compound 5, 2-(Naphthalen-1-Yl-Oxalyl-Amino)-Benzoicacid
  • 6-(Oxalyl-Amino)-1h-Indole-5-Carboxylic Acid
  • 2-[{4-[(2S)-2-{[(Allyloxy)carbonyl]amino}-3-({4-[3-hydroxy-2-(methoxycarbonyl)phenoxy]butyl}amino)-3-oxopropyl]phenyl}(carboxycarbonyl)amino]benzoic acid
  • 3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid Dimethylamide
  • [(4-{4-[4-(Difluoro-Phosphono-Methyl)-Phenyl]-Butyl}-Phenyl)-Difluoro-Methyl]-Phosphonic Acid
  • {4-[(2s,4e)-2-(1,3-Benzothiazol-2-Yl)-2-(1h-1,2,3-Benzotriazol-1-Yl)-5-Phenylpent-4-Enyl]Phenyl}(Difluoro)Methylphosphonic Acid
  • N-(3-Carboxypropanoyl)-L-phenylalanyl-3-carboxy-O-(carboxymethyl)-N-pentyl-L-tyrosinamide
  • 1-METHYL-3-PHENYL-1H-PYRAZOL-5-YLSULFAMIC ACID
  • ISIS 113715
  • Trodusquemine
  • Ertiprotafib
  • 4-BROMO-3-(CARBOXYMETHOXY)-5-[3-(CYCLOHEXYLAMINO)PHENYL]THIOPHENE-2-CARBOXYLIC ACID
  • [(3S)-3-(Methylcarbamoyl)-2-{[(2-methyl-2-propanyl)oxy]carbonyl}-1,2,3,4-tetrahydro-7-isoquinolinyl]sulfamic acid
  • 4-BROMO-3-(CARBOXYMETHOXY)-5-PHENYLTHIOPHENE-2-CARBOXYLIC ACID
  • 5-(4-CHLORO-5-PHENYL-3-THIENYL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE
  • 4-BROMO-3-(CARBOXYMETHOXY)-5-(4-HYDROXYPHENYL)THIOPHENE-2-CARBOXYLIC ACID
  • [{2-bromo-4-[(2R)-3-oxo-2,3-diphenylpropyl]phenyl}(difluoro)methyl]phosphonic acid
  • 5-[3-(BENZYLAMINO)PHENYL]-4-BROMO-3-(CARBOXYMETHOXY)THIOPHENE-2-CARBOXYLIC ACID
  • 2-[(7-HYDROXY-NAPHTHALEN-1-YL)-OXALYL-AMINO]-BENZOIC ACID
  • 3-(CARBOXYMETHOXY)THIENO[2,3-B]PYRIDINE-2-CARBOXYLIC ACID
  • 4-PHOSPHONOOXY-PHENYL-METHYL-[4-PHOSPHONOOXY]BENZEN
  • N-ACETYL-L-PHENYLALANYL-4-[DIFLUORO(PHOSPHONO)METHYL]-L-PHENYLALANINAMIDE
  • [(3R)-3-(Methylcarbamoyl)-2-{[(2-methyl-2-propanyl)oxy]carbonyl}-1,2,3,4-tetrahydro-7-isoquinolinyl]sulfamic acid
  • 5-(3-HYDROXYPHENYL)ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDE
  • 5-(3-{3-[3-HYDROXY-2-(METHOXYCARBONYL)PHENOXY]PROPENYL}PHENYL)-4-(HYDROXYMETHYL)ISOXAZOLE-3-CARBOXYLIC ACID
  • ISOTHIAZOLIDINONE ANALOG
  • 4-[3-(dibenzylamino)phenyl]-2,4-dioxobutanoic acid
  • p-Benzoyl-L-phenylalanine
  • 6-(DIFLUORO-PHOSPHONO-METHYL)-NAPHTHALENE-2-CARBOXYLIC ACID
  • (3R)-METHYLCARBAMOYL-7-SULFOAMINO-3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLIC ACID BENZYL ESTER
  • 5-(4-METHOXYBIPHENYL-3-YL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE
  • 1,2,5-THIADIAZOLIDIN-3-ONE-1,1-DIOXIDE
  • (4-{(2S)-2-[(tert-butoxycarbonyl)amino]-3-methoxy-3-oxopropyl}phenyl)methaneseleninic acid
PTPN6 protein tyrosine phosphatase non-receptor type 6
  • GPVI-mediated activation cascade
  • Regulation of KIT signaling
  • PECAM1 interactions
  • Costimulation by the CD28 family
  • PD-1 signaling
  • Signal regulatory protein family interactions
  • Platelet sensitization by LDL
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • CD22 mediated BCR regulation
  • Neutrophil degranulation
  • Interferon gamma signaling
  • Regulation of IFNG signaling
  • Interleukin-37 signaling
  • Interferon alpha/beta signaling
  • Interleukin receptor SHC signaling
  • Regulation of IFNA signaling
  • Growth hormone receptor signaling
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Tiludronic acid
RAC3 Rac family small GTPase 3
  • Rho GTPase cycle
  • PCP/CE pathway
RACK1 receptor for activated C kinase 1
  • Regulation of TNFR1 signaling
  • TNFR1-induced NFkappaB signaling pathway
  • TNFR1-mediated ceramide production
  • Copper
RANBP9 RAN binding protein 9
  • L1CAM interactions
  • RAF/MAP kinase cascade
  • MET activates RAS signaling
RARA retinoic acid receptor alpha
  • Nuclear Receptor transcription pathway
  • SUMOylation of intracellular receptors
  • Signaling by Retinoic Acid
  • Activation of anterior HOX genes in hindbrain development during early embryogenesis
  • Transcriptional regulation of granulopoiesis
  • Transcriptional regulation of granulopoiesis
  • Adapalene
  • Acitretin
  • Alitretinoin
  • Tretinoin
  • Tazarotene
  • Etretinate
  • Isotretinoin
  • Tamibarotene
  • LGD-1550
  • Trifarotene
  • Isolated orofacial clefts, including: Cleft lip with or without cleft palate; Cleft palate
  • Acute myeloid leukemia (AML)
RBBP4 RB binding protein 4, chromatin remodeling factor
  • Transcription of E2F targets under negative control by DREAM complex
  • Transcription of E2F targets under negative control by DREAM complex
  • Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1
  • G0 and Early G1
  • Polo-like kinase mediated events
  • PRC2 methylates histones and DNA
  • Oxidative Stress Induced Senescence
  • HDACs deacetylate histones
  • PKMTs methylate histone lysines
  • ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression
  • Activation of anterior HOX genes in hindbrain development during early embryogenesis
  • Deposition of new CENPA-containing nucleosomes at the centromere
  • Regulation of TP53 Activity through Acetylation
  • Cyclin E associated events during G1/S transition
  • G1/S-Specific Transcription
  • Cyclin A:Cdk2-associated events at S phase entry
  • RNA Polymerase I Transcription Initiation
  • Regulation of PTEN gene transcription
  • Regulation of PTEN gene transcription
  • Transcriptional Regulation by E2F6
  • HCMV Early Events
  • Potential therapeutics for SARS
RBBP7 RB binding protein 7, chromatin remodeling factor
  • PRC2 methylates histones and DNA
  • Oxidative Stress Induced Senescence
  • HDACs deacetylate histones
  • PKMTs methylate histone lysines
  • HATs acetylate histones
  • RMTs methylate histone arginines
  • ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression
  • Activation of anterior HOX genes in hindbrain development during early embryogenesis
  • Deposition of new CENPA-containing nucleosomes at the centromere
  • Regulation of TP53 Activity through Acetylation
  • RNA Polymerase I Transcription Initiation
  • Regulation of PTEN gene transcription
  • Regulation of PTEN gene transcription
  • Neddylation
  • Transcriptional Regulation by E2F6
  • HCMV Early Events
  • Potential therapeutics for SARS
RBFOX2 RNA binding fox-1 homolog 2
  • FGFR2 alternative splicing
RBM23 RNA binding motif protein 23
RBM39 RNA binding motif protein 39
RELA RELA proto-oncogene, NF-kB subunit
  • Activation of NF-kappaB in B cells
  • RIP-mediated NFkB activation via ZBP1
  • Regulated proteolysis of p75NTR
  • Downstream TCR signaling
  • NF-kB is activated and signals survival
  • Senescence-Associated Secretory Phenotype (SASP)
  • FCERI mediated NF-kB activation
  • DEx/H-box helicases activate type I IFN and inflammatory cytokines production
  • PKMTs methylate histone lysines
  • Transcriptional regulation of white adipocyte differentiation
  • TAK1 activates NFkB by phosphorylation and activation of IKKs complex
  • Interleukin-1 processing
  • SUMOylation of immune response proteins
  • IkBA variant leads to EDA-ID
  • Dectin-1 mediated noncanonical NF-kB signaling
  • CLEC7A (Dectin-1) signaling
  • CD209 (DC-SIGN) signaling
  • CLEC7A/inflammasome pathway
  • The NLRP3 inflammasome
  • Transcriptional Regulation by VENTX
  • Interleukin-1 signaling
  • TRAF6 mediated NF-kB activation
  • Purinergic signaling in leishmaniasis infection
  • Dimethyl fumarate
  • SC-236
REXO4 REX4 homolog, 3'-5' exonuclease
RFX4 regulatory factor X4
RGS3 regulator of G protein signaling 3
  • G alpha (q) signalling events
  • G alpha (i) signalling events
RLIM ring finger protein, LIM domain interacting
  • Antigen processing: Ubiquitination & Proteasome degradation
RNF14 ring finger protein 14
  • Antigen processing: Ubiquitination & Proteasome degradation

Page 14 out of 19 pages